Lantheus - LNTH Stock Forecast, Price & News

6 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Lantheus in the last twelve months. There are currently 6 buy ratings for the stock. The consensus among Wall Street analysts is that investors should "buy" LNTH shares.
View LNTH analyst ratings or view top-rated stocks.

6 equities research analysts have issued 12-month target prices for Lantheus' stock. Their LNTH share price forecasts range from $91.00 to $120.00. On average, they expect the company's share price to reach $107.33 in the next twelve months. This suggests a possible upside of 35.6% from the stock's current price.
View analysts price targets for LNTH or view top-rated stocks among Wall Street analysts.

Lantheus' stock was trading at $50.96 at the beginning of the year. Since then, LNTH shares have increased by 55.4% and is now trading at $79.18.
View the best growth stocks for 2023 here.

Lantheus saw a increase in short interest during the month of February. As of February 28th, there was short interest totaling 3,720,000 shares, an increase of 32.9% from the February 13th total of 2,800,000 shares. Based on an average daily volume of 1,130,000 shares, the days-to-cover ratio is presently 3.3 days. Approximately 5.6% of the shares of the company are short sold.
View Lantheus' Short Interest.

The company is scheduled to release its next quarterly earnings announcement on Friday, May 5th 2023.
View our LNTH earnings forecast.

Lantheus Holdings, Inc. (NASDAQ:LNTH) posted its earnings results on Thursday, February, 23rd. The medical equipment provider reported $1.28 earnings per share (EPS) for the quarter, topping analysts' consensus estimates of $0.87 by $0.41. The medical equipment provider earned $263.17 million during the quarter, compared to the consensus estimate of $244.61 million. Lantheus had a trailing twelve-month return on equity of 51.60% and a net margin of 3.00%.

ETFs with the largest weight of Lantheus (NASDAQ:LNTH) stock in their portfolio include Harbor Health Care ETF (MEDI), AdvisorShares Dorsey Wright Alpha Equal Weight ETF (DWEQ), SPDR S&P Health Care Equipment ETF (XHE), Inspire Fidelis Multi Factor ETF (FDLS), Invesco S&P MidCap 400 Pure Growth ETF (RFG), AdvisorShares Alpha DNA Equity Sentiment ETF (SENT), Pacer Lunt MidCap Multi-Factor Alternator ETF (PAMC) and First Trust Active Factor Small Cap ETF (AFSM).

Lantheus issued an update on its first quarter 2023 earnings guidance on Thursday, February, 23rd. The company provided EPS guidance of $1.28-$1.32 for the period, compared to the consensus EPS estimate of $1.06. The company issued revenue guidance of $280.00 million-$285.00 million, compared to the consensus revenue estimate of $253.59 million.

4 employees have rated Lantheus Chief Executive Officer Mary Anne Heino on Glassdoor.com. Mary Anne Heino has an approval rating of 51% among the company's employees. This puts Mary Anne Heino in the bottom 25% of approval ratings compared to other CEOs of publicly-traded companies.

Based on aggregate information from My MarketBeat watchlists, some companies that other Lantheus investors own include (MBBYF) (MBBYF), Energy Transfer (ET), Paratek Pharmaceuticals (PRTK), Catalyst Pharmaceuticals (CPRX), Amicus Therapeutics (FOLD), Anavex Life Sciences (AVXL), Exelixis (EXEL), Gerdau (GGB), Pieris Pharmaceuticals (PIRS) and Abeona Therapeutics (ABEO).

(LNTH) raised $75 million in an initial public offering (IPO) on Thursday, June 25th 2015. The company issued 7,900,000 shares at $8.50-$10.50 per share. Citigroup, Jefferies, RBC Capital Markets and Wells Fargo Securities acted as the underwriters for the IPO and Baird was co-manager.

Lantheus trades on the NASDAQ under the ticker symbol "LNTH."

Lantheus' stock is owned by a variety of institutional and retail investors. Top institutional investors include Alliancebernstein L.P. (4.64%), Dimensional Fund Advisors LP (2.10%), Geode Capital Management LLC (1.89%), Silvercrest Asset Management Group LLC (1.63%), T. Rowe Price Investment Management Inc. (1.54%) and Price T Rowe Associates Inc. MD (1.51%). Insiders that own company stock include Andrea Sabens, Brian A Markison, Carol Walker, Daniel Niedzwiecki, Etienne Montagut, Gerard Ber, Heinz Christoph Maeusli, John J Bolla, Mary Anne Heino, Michael P Duffy, Michael P Duffy, Paul Blanchfield, Robert J Jr Marshall and Sam R Leno.
View institutional ownership trends.

Shares of LNTH stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.

One share of LNTH stock can currently be purchased for approximately $79.18.

Lantheus (NASDAQ:LNTH) has a market capitalization of $5.35 billion and generates $935.06 million in revenue each year. The medical equipment provider earns $28.07 million in net income (profit) each year or $0.34 on an earnings per share basis.

The company employs 612 workers across the globe.

Lantheus' mailing address is 331 TREBLE COVE ROAD, NORTH BILLERICA MA, 01862. The official website for the company is www.lantheus.com. The medical equipment provider can be reached via phone at (978) 671-8001, via email at ir@lantheus.com, or via fax at 978-671-8860.